Epigenetics and immune cells in medulloblastoma.
brain tumor microenvironment
epigenetics
immune cells
immunotherapeutics
medulloblastoma
Journal
Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621
Informations de publication
Date de publication:
2023
2023
Historique:
received:
31
12
2022
accepted:
27
02
2023
entrez:
27
3
2023
pubmed:
28
3
2023
medline:
28
3
2023
Statut:
epublish
Résumé
Medulloblastoma (MB) is a highly malignant childhood tumor of the cerebellum. Transcriptional and epigenetic signatures have classified MB into four molecular subgroups, further stratified into biologically different subtypes with distinct somatic copy-number aberrations, driver genes, epigenetic alterations, activated pathways, and clinical outcomes. The brain tumor microenvironment (BTME) is of importance to regulate a complex network of cells, including immune cells, involved in cancer progression in brain malignancies. MB was considered with a "cold" immunophenotype due to the low influx of immune cells across the blood brain barrier (BBB). Recently, this assumption has been reconsidered because of the identification of infiltrating immune cells showing immunosuppressive phenotypes in the BTME of MB tumors. Here, we are providing a comprehensive overview of the current status of epigenetics alterations occurring during cancer progression with a description of the genomic landscape of MB by focusing on immune cells within the BTME. We further describe how new immunotherapeutic approaches could influence concurring epigenetic mechanisms of the immunosuppressive cells in BTME. In conclusion, the modulation of these molecular genetic complexes in BTME during cancer progression might enhance the therapeutic benefit, thus firing new weapons to fight MB.
Identifiants
pubmed: 36968588
doi: 10.3389/fgene.2023.1135404
pii: 1135404
pmc: PMC10036437
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1135404Informations de copyright
Copyright © 2023 Gorini, Miceli, de Antonellis, Amente, Zollo and Ferrucci.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Acta Neuropathol. 2013 Mar;125(3):373-84
pubmed: 23184418
Nat Rev Genet. 2011 Apr;12(4):283-93
pubmed: 21358745
Neurosci Lett. 2017 Apr 3;645:106-112
pubmed: 28259657
J Biomed Sci. 2019 Oct 20;26(1):78
pubmed: 31629410
Nat Commun. 2015 Dec 15;6:10204
pubmed: 26667266
Cell. 2018 May 31;173(6):1549
pubmed: 29856958
Cancer Cell. 2017 Jun 12;31(6):737-754.e6
pubmed: 28609654
Cold Spring Harb Perspect Med. 2016 Oct 3;6(10):
pubmed: 27599530
Nature. 2014 Jun 26;510(7506):537-41
pubmed: 24847876
J Immunother Cancer. 2018 Apr 30;6(1):30
pubmed: 29712574
Clin Epigenetics. 2021 Aug 27;13(1):166
pubmed: 34452630
Acta Neuropathol. 2010 Sep;120(3):305-16
pubmed: 20652577
Nature. 2022 Sep;609(7929):1012-1020
pubmed: 36131015
Int J Cancer. 2008 Mar 15;122(6):1207-13
pubmed: 18058815
Nat Rev Genet. 2012 Apr 03;13(5):343-57
pubmed: 22473383
J Transl Med. 2019 Sep 23;17(1):321
pubmed: 31547819
Nat Commun. 2021 May 11;12(1):2582
pubmed: 33976133
Cancer Res. 2002 Oct 15;62(20):5906-11
pubmed: 12384556
Pharmacol Res Perspect. 2014 Jun;2(3):e00043
pubmed: 25505589
Clin Cancer Res. 2015 Mar 15;21(6):1457-65
pubmed: 25344580
Front Cell Neurosci. 2018 Aug 03;12:243
pubmed: 30123114
Toxicol Lett. 2014 Mar 21;225(3):488-97
pubmed: 24440346
Lancet Oncol. 2016 Apr;17(4):484-495
pubmed: 26976201
Blood Cancer J. 2013 Sep 06;3:e143
pubmed: 24013664
Oncol Lett. 2020 Dec;20(6):397
pubmed: 33193857
Curr Neurol Neurosci Rep. 2007 Mar;7(2):130, 132
pubmed: 17324362
Mol Cancer Ther. 2015 Mar;14(3):727-39
pubmed: 25552369
Cerebellum. 2018 Feb;17(1):28-36
pubmed: 29178021
Neoplasia. 2020 Apr 24;22(6):231-241
pubmed: 32339949
Nat Med. 2014 Jul;20(7):732-40
pubmed: 24973920
J Leukoc Biol. 2014 Feb;95(2):357-67
pubmed: 24068730
Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):E3458-66
pubmed: 25082897
J Neurosci. 2007 Oct 3;27(40):10714-21
pubmed: 17913905
Invest New Drugs. 2017 Feb;35(1):26-36
pubmed: 27785591
J Pathol. 2017 Jan;241(1):10-24
pubmed: 27770445
J Clin Oncol. 2011 Apr 10;29(11):1408-14
pubmed: 20823417
Anticancer Res. 2007 Jan-Feb;27(1A):465-70
pubmed: 17352268
Epigenomics. 2020 Jan;12(2):157-169
pubmed: 31849241
Transl Pediatr. 2020 Apr;9(2):157-162
pubmed: 32477916
Bioorg Chem. 2020 Jun;99:103808
pubmed: 32334189
Biochem Pharmacol. 2017 Aug 1;137:61-80
pubmed: 28431938
J Clin Oncol. 2016 Dec;34(34):4151-4160
pubmed: 27863192
Nat Rev Dis Primers. 2019 Feb 14;5(1):11
pubmed: 30765705
Cancer Biol Ther. 2016 Dec;17(12):1253-1265
pubmed: 27834580
PLoS One. 2013 Oct 21;8(10):e78045
pubmed: 24205083
PLoS One. 2013 Aug 05;8(8):e71754
pubmed: 23940785
Neuro Oncol. 2007 Apr;9(2):135-44
pubmed: 17329407
J Neuropathol Exp Neurol. 2018 Aug 1;77(8):696-702
pubmed: 29878245
Nat Genet. 2019 Dec;51(12):1702-1713
pubmed: 31768071
Science. 2007 Oct 19;318(5849):447-50
pubmed: 17761849
J Pediatr Hematol Oncol. 2019 May;41(4):e235-e241
pubmed: 30681550
J Immunol. 2009 Jan 1;182(1):259-73
pubmed: 19109157
Oncotarget. 2013 Nov;4(11):2080-95
pubmed: 24231268
Lancet Oncol. 2018 Dec;19(12):1602-1616
pubmed: 30392813
Cancer Immunol Immunother. 2017 Dec;66(12):1589-1595
pubmed: 28825123
Mol Cancer Ther. 2005 Dec;4(12):1912-22
pubmed: 16373706
Nature. 2022 Sep;609(7929):901-903
pubmed: 36131054
Cell. 2006 Apr 21;125(2):301-13
pubmed: 16630818
Lancet Oncol. 2017 Jul;18(7):958-971
pubmed: 28545823
Cancers (Basel). 2022 Oct 13;14(20):
pubmed: 36291792
EMBO J. 2011 Jan 19;30(2):249-62
pubmed: 21131905
Int J Cancer. 2012 Oct 15;131(8):1800-9
pubmed: 22287205
Oncogene. 2009 Sep 3;28(35):3097-110
pubmed: 19597472
J Immunol. 2007 Jul 15;179(2):845-53
pubmed: 17617575
Diseases. 2019 Nov 01;7(4):
pubmed: 31683808
Clin Cancer Res. 2016 Feb 1;22(3):582-95
pubmed: 26405194
Cancer Cell. 2008 Aug 12;14(2):135-45
pubmed: 18691548
Front Oncol. 2021 Jun 08;11:660892
pubmed: 34168987
World J Stem Cells. 2021 Jul 26;13(7):670-684
pubmed: 34367473
Expert Opin Drug Discov. 2015 Jun;10(6):599-613
pubmed: 25895649
Front Pediatr. 2018 Dec 03;6:370
pubmed: 30560106
Genes Dev. 2012 Apr 15;26(8):751-5
pubmed: 22508723
Cytotherapy. 2017 Mar;19(3):408-418
pubmed: 28109751
Biomolecules. 2021 Feb 18;11(2):
pubmed: 33670563
Cancer Res. 2002 Nov 1;62(21):6108-15
pubmed: 12414635
Cancer Cell. 2017 Mar 13;31(3):326-341
pubmed: 28292436
Nature. 2012 Aug 2;488(7409):100-5
pubmed: 22832583
Nat Rev Cancer. 2015 Jun;15(6):334-46
pubmed: 25998713
Lancet Oncol. 2006 Oct;7(10):813-20
pubmed: 17012043
Nature. 2017 Jul 19;547(7663):311-317
pubmed: 28726821
Oncogene. 2011 May 12;30(19):2275-81
pubmed: 21562496
Int J Mol Sci. 2014 Jun 18;15(6):11013-29
pubmed: 24945311
Brain Pathol. 2013 Mar;23(2):193-9
pubmed: 23432644
Oncoimmunology. 2018 May 24;7(9):e1462430
pubmed: 30228931
Nat Genet. 2009 Apr;41(4):465-72
pubmed: 19270706
Nat Genet. 2012 Jan 29;44(3):251-3
pubmed: 22286216
Oncogene. 2021 Jan;40(2):396-407
pubmed: 33159168
Cancer Res. 2009 Dec 15;69(24):9211-8
pubmed: 19934320
Mol Cell Neurosci. 2018 Mar;87:65-76
pubmed: 29269116
Eur J Cancer. 2002 Jan;38(1):83-91
pubmed: 11750844
Cell Death Differ. 2014 Mar;21(3):369-80
pubmed: 24212761
Eur J Immunol. 2007 Nov;37(11):3190-6
pubmed: 17918205
Acta Neuropathol. 2012 Apr;123(4):473-84
pubmed: 22358457
J Hematol Oncol. 2019 Dec 4;12(1):129
pubmed: 31801559
Cell Rep. 2022 Aug 2;40(5):111162
pubmed: 35926460
Nature. 2012 Aug 2;488(7409):43-8
pubmed: 22722829
Front Oncol. 2021 Oct 22;11:758146
pubmed: 34745995
Sci Rep. 2017 Jul 26;7(1):6554
pubmed: 28747667
Cell. 2020 Feb 6;180(3):502-520.e19
pubmed: 31983537
J Neurooncol. 2012 Dec;110(3):335-48
pubmed: 23054560
Cancer Res. 2016 Oct 1;76(19):5671-5682
pubmed: 27530322
Oncoimmunology. 2017 Nov 27;7(3):e1398877
pubmed: 29399402
Cell. 2007 Feb 23;128(4):735-45
pubmed: 17320510
Cell. 2020 Jun 25;181(7):1643-1660.e17
pubmed: 32470396
Blood. 2011 Dec 1;118(23):6050-6
pubmed: 21984804
Acta Neuropathol. 2012 Apr;123(4):465-72
pubmed: 22134537
J Clin Invest. 2011 Oct;121(10):4043-55
pubmed: 21946257
Nat Cell Biol. 2010 Feb;12(2):132-42
pubmed: 20081843
Immunity. 2010 May 28;32(5):593-604
pubmed: 20510870
J Clin Oncol. 2005 Nov 1;23(31):7951-7
pubmed: 16258095
Clin Exp Metastasis. 2012 Apr;29(4):381-95
pubmed: 22322279
Neoplasia. 2011 Apr;13(4):374-85
pubmed: 21472142
Nat Commun. 2019 Jun 3;10(1):2410
pubmed: 31160587
Cell Rep. 2021 Mar 30;34(13):108917
pubmed: 33789113
Neuro Oncol. 2021 Sep 1;23(9):1586-1596
pubmed: 33823018
Nat Immunol. 2010 Oct;11(10):936-44
pubmed: 20729857
Int J Oncol. 2006 Mar;28(3):755-66
pubmed: 16465382
Clin Exp Metastasis. 2012 Aug;29(6):585-601
pubmed: 22484917
Acta Neuropathol. 2023 Jan;145(1):97-112
pubmed: 36459208
Nat Med. 2021 Sep;27(9):1544-1552
pubmed: 34253928
J Clin Oncol. 2012 Jul 20;30(21):2648-53
pubmed: 22665539
Int J Cancer. 2016 Nov 1;139(9):2047-55
pubmed: 27388964
Front Immunol. 2022 Jan 24;13:836223
pubmed: 35140725
J Neurooncol. 2016 Jan;126(2):371-6
pubmed: 26514358
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
Exp Hematol Oncol. 2019 Nov 15;8:30
pubmed: 31788346
Brain. 2018 May 1;141(5):1300-1319
pubmed: 29490009
Nature. 2016 Feb 4;530(7588):57-62
pubmed: 26814967
Curr Treat Options Oncol. 2021 Jul 30;22(9):83
pubmed: 34328587
Oncotarget. 2017 Aug 2;8(40):68557-68570
pubmed: 28978137
Neuro Oncol. 2020 May 15;22(5):625-638
pubmed: 31729527
Nature. 2022 Sep;609(7929):1021-1028
pubmed: 36131014
Front Immunol. 2019 Oct 01;10:2294
pubmed: 31632393
Lancet Oncol. 2013 Nov;14(12):1147-8
pubmed: 24140202
Front Immunol. 2021 Apr 02;12:640369
pubmed: 33868269
Sci Transl Med. 2017 Mar 15;9(381):
pubmed: 28298418
Epigenetics. 2017 May 4;12(5):353-369
pubmed: 28059591
Acta Neuropathol. 2013 Mar;125(3):385-94
pubmed: 23179372
Protein Sci. 2017 May;26(5):997-1011
pubmed: 28218430
Nat Commun. 2020 Aug 28;11(1):4324
pubmed: 32859926
J Neurooncol. 2011 Jun;103(2):287-96
pubmed: 20853133
Oncogene. 2015 Sep 3;34(36):4746-57
pubmed: 25531316
BMC Cancer. 2010 Nov 08;10:614
pubmed: 21059263
Nature. 2014 Jul 24;511(7510):428-34
pubmed: 25043047
Nature. 2006 May 18;441(7091):349-53
pubmed: 16625203
Nature. 2012 Aug 2;488(7409):106-10
pubmed: 22820256
Cancer Res. 2002 Jul 1;62(13):3794-7
pubmed: 12097291
Nat Commun. 2019 Jan 18;10(1):332
pubmed: 30659187
Nature. 2012 Jan 29;482(7384):226-31
pubmed: 22286061
Neuro Oncol. 2022 Feb 1;24(2):273-286
pubmed: 34077540
Cell Rep. 2017 Oct 3;21(1):154-167
pubmed: 28978469
Cureus. 2016 May 21;8(5):e620
pubmed: 27382528
Cell Rep. 2017 Mar 21;18(12):2907-2917
pubmed: 28329683
Acta Neuropathol. 2013 Mar;125(3):359-71
pubmed: 23291781
Nucleic Acids Res. 2007;35(7):e51
pubmed: 17344319
Carcinogenesis. 2015 Dec;36(12):1453-63
pubmed: 26449251
iScience. 2020 Jun 26;23(6):101250
pubmed: 32629615
Cancer Cell. 2016 Apr 11;29(4):508-522
pubmed: 27050100
Adv Biomed Res. 2019 Oct 31;8:63
pubmed: 31737580
Mutat Res. 2007 Dec 1;625(1-2):134-44
pubmed: 17669439
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Nature. 2010 Dec 23;468(7327):1095-9
pubmed: 21150899
J Neurooncol. 2015 Oct;125(1):65-74
pubmed: 26311248
Epigenomics. 2016 Dec;8(12):1671-1687
pubmed: 27700179
Cold Spring Harb Perspect Med. 2016 Nov 1;6(11):
pubmed: 27638352
Genes Dev. 2022 May 1;36(9-10):514-532
pubmed: 35680424
Cell. 2012 Jan 20;148(1-2):59-71
pubmed: 22265402
Front Oncol. 2013 Apr 19;3:94
pubmed: 23626949
Neuro Oncol. 2019 Sep 6;21(9):1150-1163
pubmed: 31111916
J Biol Chem. 2007 Jul 13;282(28):20395-406
pubmed: 17500065
Acta Neuropathol. 2019 Aug;138(2):309-326
pubmed: 31076851
iScience. 2020 Dec 13;24(1):101938
pubmed: 33426510
Clin Epigenetics. 2017 May 30;9:59
pubmed: 28572863
Immunotherapy. 2011 Dec;3(12):1445-59
pubmed: 22091681